Key statistics
On Friday, NervGen Pharma Corp (NGEN:CVE) closed at 5.74, -32.39% below its 52-week high of 8.49, set on Jan 08, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 5.59 |
|---|---|
| High | 5.85 |
| Low | 5.58 |
| Bid | 5.70 |
| Offer | 5.80 |
| Previous close | 5.60 |
| Average volume | 83.42k |
|---|---|
| Shares outstanding | 80.39m |
| Free float | 63.40m |
| P/E (TTM) | -- |
| Market cap | 461.43m CAD |
| EPS (TTM) | -0.3622 CAD |
Data delayed at least 15 minutes, as of Feb 13 2026 20:59 GMT.
More ▼
Announcements
- NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
- NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
- NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
- NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
- NervGen Pharma Begins Trading on Nasdaq Today
- NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
More ▼
